marketing wars over the new sleeping pills

You'll see marketing wars over the new sleeping pills... Lunesta, Rozerem, Ambien CR, and then indiplon next year.

Lunesta (eszopiclone) is making a big splash now to get a head start. It's the first one not limited to short-term use... but some patients complain about a bitter aftertaste.

Rozerem (ro-ZER-um) will be out this month. It's the first in a new class...melatonin receptor agonists.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote